Glioblastomas with oligodendroglial component have the same clinical phenotype as classical glioblastomas

British Journal of Neurosurgery

Volumn 27, Issue 4, 2013, Pages 419-424

  Elmahdi, Ashraf ^a   Frary, Amy J ^a   Scotton, William J ^a   O'Donovan, Dominic G ^a   Price, Stephen J ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Glioblastoma; Heterogeneity; Oligodendroglial tumour; Prognosis; Tumour pathology

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FRONTAL LOBE; GLIOBLASTOMA; GLIOSARCOMA; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; OLIGODENDROGLIA; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; FRONTAL LOBE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OLIGODENDROGLIOMA; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881423063     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2013.767315     Document Type: Article

References (18)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. W HO Classifi cation of Tumours of the Central Nervous System. Lyon: IARC, 2007.
2. Guilfoyle MR, Weerakkody RA, Oswal A, et al. Implementation of neuro-oncology service reconfi guration in accordance with NICE guidance provides enhanced clinical care for patients with glioblastoma multiforme. Br J Cancer 2011; 104: 1810-5.
3. Bigner DD. Biology of gliomas: potential clinical implications of glioma cellular heterogeneity. Neurosurgery 1981; 9: 320-6.
4. Klink B, Schlingelhof B, Klink M, Stout-Weider K, Patt S, Schrock E. Glioblastomas with oligodendroglial component-common origin of the diff erent histological parts and genetic subclassifi cation. Cell Oncol 2011; 34: 261-75.
5. Burnet NG, Lynch AG, Jeff eries SJ, et al. High grade glioma: Imaging combined with pathological grade defi nes management and predicts prognosis. Radiother Oncol 2007; 85: 371-8.
6. Salvati M, Formichella A, D Elia A, et al. Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. J Neuro- Oncol 2009; 94: 129-34.
7. H ilton D A, P enney M, P obereskin L, S anders H, L ove S. H istological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial diff erentiation indicate improved survival. Histopathology 2004; 44: 555-60.
8. Wang Y, Li S, Chen L, et al. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol 2012; 14: 518-25.
9. P into L, M ahler Araujo M, V ettore A, et al. Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Archiv 2008; 452: 481-90.
10. N akamura H, M akino K, K uratsu J. M olecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO). Brain Tumor Pathol 2011; 28: 185-90.
11. H egi M E, J anzer R C, L ambiv W L, et al. P resence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifi es a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC-26981/ NCIC-CE.3 trial. Acta neuropathol. 2012; 123: 841-52.
12. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001; 60: 863-71.
13. H omma T, F ukushima T, V accarella S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 2006; 65: 846-54.
14. Vordermark D, Ruprecht K, Rieckmann P, et al. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer 2006; 6: 247.
15. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progressionfree survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ha se III trial. J ClinOncol 2006; 24: 2715-22.
16. Bruner JM, Inouye L, Fuller GN, Langford LA. Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer 1997; 79: 796-803.
17. Murphy M, Loosemore A, Ferrer I, Wesseling P, Wilkins PR, Bell BA. Neuropathological diagnostic accuracy. Br J Neurosurg 2002; 16: 461-4.
18. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classifi cation and grading of primary gliomas. Cancer 1997; 79: 1381-93.